Mangoceuticals, Inc. Announces TV Air Dates for Interview Featuring CEO Jacob Cohen on Fox Business, Bloomberg TV, and Newsmax TV
Dallas, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is pleased to announce air dates for the first episode of a multi-part TV series on FMW Media’s “New To The Street” business TV show featuring an in-depth interview with Mangoceuticals, Inc.’s CEO, Jacob Cohen.
The interview was filmed at the Nasdaq MarketSite Studio and will air on Fox Business Network, Bloomberg TV (as a sponsored program), and Newsmax TV (through its syndicated and sponsored networks) as follows:
- July 22 at 3:30 p.m. ET on Newsmax TV
- July 24 at 10:30 p.m. PT on Fox Business
- August 5 at 6 p.m. ET on Bloomberg TV
Jane King, the host of New To The Street, sat down with Mr. Cohen to discuss Mangoceuticals’ vision, including how the Company identified its market opportunity and how it plans to execute its business plan in strategic planning terms.
In the interview, Mr. Cohen began by noting that the rise of direct-to-consumer telemedicine as an emerging pathway has attracted tremendous interest and the formation of many new businesses focused on selling health and wellness products through expanding telemedicine platforms.
But that the current product offerings amongst the competition in the market lacked innovation. MangoRx is predicated, in part, on stepping into that equation and introducing something capable of capitalizing on the emergence of direct-to-consumer telemedicine platforms while simultaneously disrupting the Men’s Health and Wellness marketplace. He points out that the Company’s first ED product represents an innovation in both formulation and in its sublingual delivery mechanism. He highlights the Company’s innovative formulation and its approach to marketing in the interview as well.
In addition to containing a proven ED pharma compound, Mango contains other ingredients that promote blood flow and intimacy. But it also offers a more efficient delivery mechanism through rapidly dissolved tablets (RDT) absorbed orally.
Mr. Cohen also discusses the Company’s unique marketing concept involving a high degree of overlap between its consumers and its investors, tying together investor relations and product marketing, which promotes additional ROI gains on capital invested in marketing efforts.
The interview expands to cover the Company’s vision for future expansion into other areas of Men’s Health and Wellness, including areas like hair loss, weight loss, mood, anti-aging, and even hormonal replacement therapies. Cohen concludes by pointing to the Company’s overall mission: to promote men’s performance in all areas and aspects of life.
FMW Media’s "New To The Street" TV brand is one of the longest-running U.S and International sponsored and Syndicated Nielsen Rated programs running today. Through its network of syndication, FMW programming reaches an estimated 540 million homes across US and international markets.
About Mango
Created using a special formulation featuring the same active ingredient as in Cialis™ (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.
Mango is a prescription medication that must be approved by a physician. After an individual has completed an online tele-health visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name "Mango" (think: "Man, Go!").
For more information, please visit www.MangoRx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen, has majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at
More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended March 31, 2023. These filings are available at www.sec.gov and at our website at https://investors.mangorx.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial
Or just click here to see why Orange is the new Blue:
https://www.mangorx.com
FOR INVESTOR RELATIONS
Fraxton Market Initiatives, LLC.
Frank Benedetto
Phone: 619-915-9422
Email: investors@mangorx.com
MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.